Emeriau Noémie, de Clippele Marie, Gailly Philippe, Tajeddine Nicolas
Laboratory of Cell Physiology, Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium.
Oncotarget. 2018 Mar 23;9(22):16059-16073. doi: 10.18632/oncotarget.24685.
SOCE (Store-Operated Calcium Entry) is the main mechanism by which external Ca enters into non-excitable cells after endoplasmic reticulum emptying. It is implicated in several processes such as proliferation and migration. Alterations in SOCE could initiate or support the development of hallmarks of cancer. In this project, we showed that disruption of the EGFR/ErbB2-dependent signalling by lapatinib and CP-724714, two inhibitors of the receptor tyrosine kinase (RTK), dramatically reduced the amplitude of the SOCE in breast cancer cells. LY294002 and MK2206, two inhibitors of the PI3K/Akt pathway, mimicked the effect of the inhibition of EGFR/ErbB2. In contrast, inhibitors of the MAPK pathway had no effect on SOCE. The involvement of EGFR/ErbB2 receptors and the PI3K/Akt pathway in the regulation of SOCE was confirmed in other cell lines derived from various cancer types. All these results showed that SOCE is positively regulated by the PI3K/Akt pathway and that this effect may be suppressed by the inhibition of the upstream RTKs. Inhibition of SOCE might therefore contribute to the anticancer effects of RTK inhibitors.
钙库操纵性钙内流(SOCE)是内质网排空后细胞外钙进入非兴奋性细胞的主要机制。它参与多种过程,如增殖和迁移。SOCE的改变可能引发或支持癌症特征的发展。在本项目中,我们发现,受体酪氨酸激酶(RTK)的两种抑制剂拉帕替尼和CP - 724714对表皮生长因子受体(EGFR)/ErbB2依赖性信号通路的破坏,显著降低了乳腺癌细胞中SOCE的幅度。PI3K/Akt通路的两种抑制剂LY294002和MK2206模拟了抑制EGFR/ErbB2的效果。相反,丝裂原活化蛋白激酶(MAPK)通路抑制剂对SOCE没有影响。在源自各种癌症类型的其他细胞系中,证实了EGFR/ErbB2受体和PI3K/Akt通路参与SOCE的调节。所有这些结果表明,SOCE受到PI3K/Akt通路的正向调节,并且这种作用可能被上游RTK的抑制所抑制。因此,抑制SOCE可能有助于RTK抑制剂的抗癌作用。